BioSpace News Archive

Alebund Pharmaceuticals (“Alebund” or the “Company”) announced phase II proof-of-concept study results for the investigational drug, AP306, a first-in-class, pan-inhibitor of sodium-dependent phosphate transporters, which was discovered by Chugai Pharmaceutical Co., Ltd., and previously referred by EOS789.

IceCure Medical Ltd. announced the publication of a study titled “Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients” in the peer-reviewed journal Annals of Surgical Oncology.

Adaptive Research, a pioneering organization committed to democratizing clinical trials by offering comprehensive support to community-based trial investigators, announced a landmark agreement with Florida Theranostics.

BioStem Technologies Inc. today announces the appointment of Mr. Thomas J. Dugan to the position of Chairman of the Board.

SeaStar Medical Holding Corporation announces the formation of the SeaStar Medical Scientific Advisory Board (SAB). The SAB is comprised of world-renowned international pediatric and adult clinical experts.

Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) today announced the commencement of patient dosing in its Phase 1-2a study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.

Halia Therapeutics today announced the dosing of the first patient in Phase 2a clinical trial evaluating its lead candidate, HT-6184, for the treatment of lower-risk myelodysplastic syndromes (LR-MDS).

Slope today announced that it has appointed Terry Edwards to the role of Chief Operating Officer.

Pioneering the future of industrial safety, Verve Motion, a Harvard University spinout, today announced it has reached a significant milestone by securing $20 million in Series B funding.

SonALAsense today announced the presentation of positive preliminary data from the ongoing Phase 1/2 SDT-201 study in Diffuse Intrinsic Pontine Glioma (DIPG).